Optimal effect-site concentration of remifentanil for inhibiting response to laryngeal mask airway removal during emergence

This randomized, controlled, double-blind study was designed to determine the optimal dose of remifentanil for preventing complications associated with the removal of a laryngeal mask airway (LMA) without delaying emergence. This study randomly assigned 128 patients to remifentanil effect-site conce...

Full description

Saved in:
Bibliographic Details
Published in:Yonsei medical journal 2015, 56(2), , pp.529-534
Main Authors: Park, Sang-Jin, Baek, Jong-Yoon, Baek, Jong-Yun, Jee, Dae-Lim
Format: Article
Language:English
Subjects:
Adult
Airway Management - methods
Anesthesia Recovery Period
Anesthetics, Intravenous - administration & dosage
Cough - prevention & control
Device Removal
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Infusions, Intravenous
Laryngeal Masks - adverse effects
Male
Middle Aged
Original
Piperidines - administration & dosage
Postoperative Complications - prevention & control
Psychomotor Agitation
Vomiting - prevention & control
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This randomized, controlled, double-blind study was designed to determine the optimal dose of remifentanil for preventing complications associated with the removal of a laryngeal mask airway (LMA) without delaying emergence. This study randomly assigned 128 patients to remifentanil effect-site concentrations (Ce) of 0 ng/mL (group R0), 0.5 ng/mL (group R0.5), 1.0 ng/mL (group R1.0), and 1.5 ng/mL (group R1.5) during emergence. The emergence and recovery profiles were recorded. Adverse events such as coughing, airway obstruction, breath-holding, agitation, desaturation, nausea, and vomiting were also evaluated. The number of patients with respiratory complications such as coughing and breath-holding was significantly lower in the R1.0 and R1.5 groups than in the R0 group (p
ISSN:0513-5796
1976-2437
DOI:10.3349/ymj.2015.56.2.529